TaiRx, Inc. Stock Price

TPEX:6580 Community·NT$1.7b Market Cap

0 Narratives written by author
0 Comments on narratives written by author
0 Fair Values set on narratives written by author

Create Narrative

6580 Share Price Performance

NT$15.00

-8.45 (-36.03%)

NT$15.00

-8.45 (-36.03%)

NT$15.00

Sat, 30 May 26

Share Pricen/a

6580 Community Narratives

There are no narratives available yet.

Create Narrative

There are no community narratives available.

Trending Discussion

Snowflake Analysis

Flawless balance sheet with slight risk.

4 Risks

0 Rewards

View Full Analysis

TaiRx, Inc. Key Details

Last Reported Earnings

Dec 31, 2025

Next Reporting Earnings

n/a

: -1.97
: 36.19%
: -793.28%
: 0%

View Full Analysis

About 6580

Founded: 2011
Employees: n/a
CEO: Du-Shieng Chien
WebsiteView website: www.trx.com.tw

TaiRx, Inc. focuses on the development and commercialization of therapeutics for the treatment of cancer and other diseases. The company’s products under development include CVM-1118, an oral anti-cancer drug that is Phase II clinical trial. Its pre-clinical products comprise TRX-920, an oral delivery formulation; and TRX-105, a molecule developed for treating and alleviating symptoms of various colitis. The company also offers Zelnite, a drug that helps in treatment of selenium deficiency; and focuses on development of the nodal diagnostic devices and anti-body drugs. The company was founded in 2011 and is based in Taipei, Taiwan.